BPC-157: Evidence, Mechanism, Dosing & Legal Status

BPC-157 ("Body Protection Compound-157," PL 14736, Bepecin) is a synthetic 15-amino-acid peptide derived from a protective protein in human gastric juice, marketed and used as a tissue-repair agent for tendon and ligament injury, gut healing, and wound recovery.1 Its popularity in fitness and recovery circles is enormous; its proof in humans is not. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. BPC-157 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is BPC-157 and how does it work?

BPC-157 is a stable gastric pentadecapeptide (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.55 Da), a partial fragment of the larger Body Protection Compound found in human gastric juice, first described by Sikirić and colleagues in 1993.1 Its triple-proline motifs and N-terminal glycine confer unusual resistance to proteolysis, which underlies its reported stability in water and gastric juice and is the rationale for oral use in gut indications.1

The core mechanism — all of it preclinical — centers on the nitric-oxide and angiogenesis axis. In a rat hind-limb ischemia model, BPC-157 increased expression of VEGF receptor-2 (VEGFR2) and accelerated blood-flow recovery, with rapid phosphorylation of eNOS in vascular endothelium.2 The proposed cascade is BPC-157 to VEGFR2 to Akt to eNOS to nitric oxide, producing endothelial proliferation, migration and tube formation.2 A complementary Src-Caveolin-1-eNOS pathway has also been described.3 Other reported signaling includes FAK-paxillin-driven cell migration, growth-hormone-receptor upregulation in tendon fibroblasts, antioxidant-protein induction, and dopaminergic and serotonergic modulation in CNS models.6 In animals the elimination half-life is under about 30 minutes; no validated human pharmacokinetic data exist.1

What is the evidence by indication?

A 2025 systematic review of musculoskeletal applications identified 35 preclinical studies and only 1 clinical study, with no completed Phase 2/3 human trials.19 Every indication below is therefore best understood as animal-model evidence, graded C.

The orthopedic evidence is the most cited and the most extrapolated. In a rat Achilles-detachment model, BPC-157 improved healing functionally, biomechanically and histologically, and recovered tendon-to-bone that did not heal spontaneously.4 A separate transection study in 72 rats showed early functional recovery via combined anti-inflammatory action and new blood-vessel formation.5 Muscle models show angiogenesis and restored muscle-to-bone reattachment.7 The gut indication is the peptide's origin: animal models show healing of ulcers, experimental colitis and NSAID-induced lesions, and early-2000s Croatian work explored BPC-157 (as PL 14736) for inflammatory bowel disease — but those human data are sparse and do not constitute completed, reportable RCTs.10

The only published human data are tiny safety pilots, not efficacy studies. An earlier Phase 1 safety/PK study (NCT02637284) had its results submission cancelled in 2016, leaving no usable public data.1 A 2025 IV pilot (n=2) gave 10 mg then 20 mg infusions with no adverse effects and no biomarker changes — a safety signal only.8 The first controlled efficacy trial, a Phase 2 RCT of subcutaneous BPC-157 for acute grade-II hamstring strain, is registered as NCT07437547 but had not reported at the time of writing.9

What doses appear in the literature?

Reported strictly as information, not a protocol. No published human dose-finding trial exists, so human dosing is extrapolated from animal work and clinician or community reports.1 Animal studies typically dose in microgram-per-kilogram to nanogram-per-kilogram ranges, once daily, by intraperitoneal, intramuscular, oral or local routes.4 Reported human subcutaneous use is commonly cited around 250 micrograms once or twice daily, with a higher band near 500 micrograms twice daily in acute-injury research planning — research-planning extrapolations, not validated human regimens.1 Oral use is reported for gastrointestinal indications on the basis of reported gastric-juice stability.1 The only published human IV exposure used 10 to 20 mg infused over an hour.8 Animal data note pain and possible necrosis when injected in aqueous or saline solution — a formulation consideration flagged in the safety literature.1

How safe is BPC-157?

Human safety data are extremely limited; fewer than about 30 people have been studied across all published reports, so rare or long-term events would not have been detected.18 Preclinically the animal safety profile is favorable: no lethal dose established up to 20 mg/kg in rats, well-tolerated repeated dosing, and no genotoxicity or embryo-fetal toxicity signals.11 The dominant theoretical risk is mechanistic — as a pro-angiogenic agent acting via VEGFR2 and EGR-1, BPC-157 could theoretically promote tumor angiogenesis, a serious caution for anyone with active or prior malignancy.1 Pregnancy, breastfeeding and pediatric use are precautionary contraindications. In practice the largest risk is often product purity: because no FDA-regulated pharmacy may currently compound it, users obtain it from research-chemical vendors whose vials have tested positive for endotoxins, heavy metals and inaccurate dosages.17

What is the FDA and WADA status in 2026?

BPC-157 is not an FDA-approved drug and has no USP/NF monograph.12 The regulatory timeline is precise: in September 2023 the FDA moved 19 compounded peptides — including BPC-157 — into 503A Category 2, effectively prohibiting their use as bulk substances.13 On April 15, 2026 the FDA removed 11 peptides, including BPC-157, from Category 2 — but because the nominations were withdrawn, not because the substances were found safe, placing BPC-157 in a gray zone: no longer prohibited, but not authorized.13 A Pharmacy Compounding Advisory Committee review is scheduled for July 23, 2026.12 The critical legal point: removal from Category 2 does not equal Category 1 status and does not authorize compounding.13

For athletes the picture is unambiguous. BPC-157 has been on the WADA Prohibited List since 2022 under category S0 (non-approved substances) — prohibited at all times, with no Therapeutic Use Exemption.14 It is detectable by mass spectrometry, real sanctions have been imposed, and the NFL, UFC and U.S. Department of Defense all prohibit it.16 Any WADA-tested athlete or service member should treat BPC-157 as banned.15

Bottom line. BPC-157 pairs a deep, coherent animal evidence base with a near-total absence of human proof. From a regenerative standpoint the rationale is appealing, but the gap between promise and proof is the headline — graded C, legally unsettled, and banned in sport. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.